Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of DO-2 in advanced or refractory MET-altered solid tumors
NL-OMON51802Phase 1Not yet recruiting
- Sponsor
- DeuterOncology
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of do-2 in Nonhematologic neoplasms, sponsored by DeuterOncology. Primary endpoints: Safety and tolerability, Maximum tolerated dose and 2 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
do-2
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON51802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51802.